Demethylating Agent Melanoma Treatment Method Using STING Signaling Enhancement
Summary
USPTO granted patent US12599621B2 to H. Lee Moffitt Cancer Center covering methods for enhancing anti-tumor T cell responses in melanoma subjects with defective STING signaling using demethylating agents. The patent, filed January 21, 2021, includes claims to methods of treatment involving demethylating agents, STING agonists, and tumor infiltrating lymphocytes. Inventors: James Mulé, Rana Falahat, Glen Barber.
What changed
USPTO granted patent US12599621B2 covering methods for enhancing anti-tumor immune responses in melanoma cells with defective STING signaling through administration of demethylating agents. The patent discloses methods for detecting reduced STING or cGAS expression in tumor biopsies and subsequent treatment with demethylating agents, optionally combined with STING agonists or tumor infiltrating lymphocytes.
For pharmaceutical and biotechnology companies developing cancer immunotherapies, this patent establishes intellectual property protection for demethylating agent-based STING pathway enhancement in melanoma treatment. Parties developing similar therapeutic approaches should conduct Freedom to Operate analyses and consider licensing opportunities to avoid infringement on the granted claims.
What to do next
- Monitor patent landscape for licensing opportunities
- Review patent claims for Freedom to Operate analysis
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Enhancing anti-tumor response in melanoma cells with defective sting signaling
Grant US12599621B2 Kind: B2 Apr 14, 2026
Assignee
H. Lee Moffitt Cancer Center
Inventors
James Mulé, Rana Falahat, Glen Barber
Abstract
Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.
CPC Classifications
A61K 31/7068 A61K 31/7084 A61K 35/17 A61K 31/7088 A61K 31/7125 A61P 35/00 A61P 17/00 C12N 5/0636 C12N 2502/30 G01N 33/5743 G01N 2333/4706 G01N 2333/91245
Filing Date
2021-01-21
Application No.
17154192
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.